ViaCyte

Biotech

Vertex buys ViaCyte for $320M, clearing out T1D competition

Vertex is absorbing ViaCyte for $320 million, taking a bulldozer to the competition of another stem cell-based treatment for diabetes.
Max Bayer Jul 11, 2022 11:45am

AltruBio snags new CMO with pivot to immunology—Chutes & Ladders

Sep 17, 2021 9:30am

ViaCyte staffs up CSO role to drive diabetes treatments

Sep 13, 2021 1:00pm

ViaCyte scores $45M for type 1 diabetes drugs in midstage trials

Jun 9, 2021 2:47pm

ViaCyte bags $80M to trial diabetes stem cell therapies

Nov 29, 2018 8:11am

CRISPR, ViaCyte team up on gene-edited diabetes treatment

Sep 17, 2018 11:12am